SynBioBeta Speaker
Derek Smith
Gilead Sciences
Principal Scientist
Derek Smith is a Principal Scientist at Gilead Sciences focused on cell line development for manufacturing biologics products. He specializes in genome engineering, cell culture process automation, and the application of novel technologies to cell line engineering that reduce the time from DNA sequence transfer to master cell bank generation.
Sessions Featuring
Derek
This Year
•
-
Human Health
Skip the Assembly, Go Straight to Your Next Breakthrough: How Innovative DNA Synthesis Is Changing What's Possible in Biopharma
The synthetic DNA field has entered an era of rapid innovation that is giving biopharma scientists new options when deciding whether to build or buy long and complex DNA. Previously hard-to-source DNA constructs are now readily available with an unprecedented guarantee for on-time shipping, eliminating procurement delays and empowering researchers to push the boundaries of synthetic biology. In this session, leading scientists will discuss how these advances are expanding design possibilities, accelerating design–build–test–learn cycles, and paving the way for the next wave of precision biotherapeutics.
Featuring
Christopher Vakulskas
Integrated DNA Technologies
Sr. Dir. of Enzyme Dev.
Colin Harvey
Hexagon Bio
Co-founder & VP, Early Discovery
Derek Smith
Gilead Sciences
Principal Scientist
Geoff Hamilton
Ansa Biotechnologies
Chief Business & CFO
•
-
Human Health
Skip the Assembly, Go Straight to Your Next Breakthrough: How Innovative DNA Synthesis Is Changing What's Possible in Biopharma
The synthetic DNA field has entered an era of rapid innovation that is giving biopharma scientists new options when deciding whether to build or buy long and complex DNA. Previously hard-to-source DNA constructs are now readily available with an unprecedented guarantee for on-time shipping, eliminating procurement delays and empowering researchers to push the boundaries of synthetic biology. In this session, leading scientists will discuss how these advances are expanding design possibilities, accelerating design–build–test–learn cycles, and paving the way for the next wave of precision biotherapeutics.
Featuring
Christopher Vakulskas
Integrated DNA Technologies
Sr. Dir. of Enzyme Dev.
Colin Harvey
Hexagon Bio
Co-founder & VP, Early Discovery
Derek Smith
Gilead Sciences
Principal Scientist
Geoff Hamilton
Ansa Biotechnologies
Chief Business & CFO
